Announcement
NeuroSearch announces revised financial calendar for 2008
The date for the announcement of the NeuroSearch third quarter report has been
changed from 19 November to 17 November and the NeuroSearch financial calendar
for the rest of 2008 is therefore now as follows:
27 August 2008: 2008 half year report
17 November 2008: Third quarter 2008 report
Thomas Hofman-Bang
Chairman of the board
Contact persons:
Flemming Pedersen, CEO, telephone: +45 4460 8214 or +45 2148 0118
Hanne Leth Hillman, Vice President, Director of IR & Corporate Communications,
telephone: +45 4460 8212 or +45 4017 5103
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX
Nordic Exchange Copenhagen A/S. The company's core business covers the
development of novel drugs, based on a broad and well-established drug discovery
platform focusing on ion channels and CNS disorders. A substantial share of its
activities is partner financed through a broad alliance with GlaxoSmithKline
(GSK) and collaborations with, among others, Abbott and Astellas. NeuroSearch's
drug pipeline comprises 14 clinical (Phase I-III) development programmes: ACR16
for Huntington's disease (Phase III), tesofensine for obesity and in Type 2
diabetes (Phase III in preparation), NS2359 for depression (Phase II) and ADHD
(Phase II) in partnership with GSK, ABT-894 for ADHD (Phase II) and pain (Phase
II) in partnership with Abbott, ACR16 for schizophrenia (Phase I) in partnership
with Astellas, ACR325 for Parkinson's disease (Phase II in preparation) and
bipolar disorder (Phase II in preparation), ABT-107 and ABT-560 for the
treatment of various CNS disorders - both (Phase I) in collaboration with
Abbott, NSD-644 for pain (Phase I) in partnership with GSK, ACR343 for
Parkinson's disease (Phase I) and NSD-788 for anxiety/depression (Phase I). In
addition, NeuroSearch has a broad portfolio of preclinical drug candidates and
holds equity interests in several biotech companies.
